- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jennifer Graff on Using Real-World Evidence to Deliver High-Quality Care
Real-world evidence helps to inform high-quality care in a number of different ways, and health information technology has really improved the quality and the caliber of real-world data available, explained Jennifer Graff, PharmD, vice president of comparative effectiveness research, National Pharmaceutical Council.
Real-world evidence helps to inform high-quality care in a number of different ways, explained Jennifer Graff, PharmD, vice president of comparative effectiveness research, National Pharmaceutical Council.
Transcript
How does real-world evidence help with informing and delivering high-quality care?
Real-world evidence helps to inform high-quality care in a number of different ways. It can help from just understanding what patients are doing. Are they adhering to their medication? It helps us understand what are the best care mechanisms, what are evidence-based care pathways that we need it set up. It helps us understand which patients are most likely to be appropriate for special care management programs, identify patients that are more likely to have better outcomes or worse side effects, and it also allows us to move into value-based payment for value-based contracts. So, real-world evidence is that crux of all the things that we do across the healthcare system.
How has the uptake of health information technology impacted the use of real-world evidence?
Health information technology has really improved the quality and the caliber of real-world data that was available. Previously, it was just based upon claims. Now, it’s based upon much richer clinical data from electronic health records, mobile apps, and other sources. So, by understanding all of this, we have much more granularity to understand how patients are doing and what works best for them.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
